Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Early Phase 1
2(50.0%)
Phase 1
2(50.0%)
4Total
Early Phase 1(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07193810Early Phase 1Recruiting

A Study of CC312 for Relapsed/Refractory Autoimmune Diseases

Role: lead

NCT06037018Phase 1Recruiting

Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

Role: lead

NCT06888960Early Phase 1Recruiting

Safety Study of CC312 in Autoimmune Disease Patients

Role: lead

NCT07177911Phase 1Recruiting

Safety and Efficacy Study of CC312 for Moderate to Severe SLE

Role: lead

All 4 trials loaded